ELVN

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 39.50 USD with a low forecast of 35.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Enliven Therapeutics Inc revenue for the last quarter amounts to -25.10M USD, decreased -7.29 % YoY.

Enliven Therapeutics Inc. EPS for the last quarter amounts to -13279000.00 USD, increased 8.71 % YoY.

Enliven Therapeutics Inc (ELVN) has 62 emplpoyees as of January 07 2026.

Today ELVN has the market capitalization of 898.52M USD.